We evaluated the therapeutic efficacy of combined treatment of Aβ-immunization with simvastatin in an Alzheimer mouse model at age 22 months. DNA prime-adenovirus boost immunization induced modest anti-Aβ titers and simvastatin increased the seropositive rate. Aβ-KLH was additionally administered to boost the titers. Irrespective of simvastatin, the immunization did not decrease cerebral Aβ deposits but increased soluble Aβ and tended to exacerbate amyloid angiopathy in the hippocampus. The immunization increased cerebral invasion of leukocytes and simvastatin counteracted the increase. Thus, modest anti-Aβ titers can increase soluble Aβ and simvastatin may reduce inflammation associated with vaccination in aged Alzheimer mouse models.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Patients with AD develop deposits of abnormally aggregated amyloid β-peptide (Aβ) as forms of amyloid plaques and cerebral amyloid angiopathy (CAA). Aβ is produced from a larger transmembrane glycoprotein, amyloid β-protein precursor (APP), by proteolytic processing. Aβ found in the AD brain is heterogeneous at its carboxylterminus, resulting in peptides of 39-43 amino acids. Amyloid plaques, however, mainly contain 2 forms of Aβ consisting of 40 (Aβ40) and 42 (Aβ42) amino acids (Iwatsubo et al., 1994; Savage et al., 1995) . Aβ42 is considered to be highly amyloidogenic, and oligomeric forms of Aβ are neurotoxic (Lambert et al., 2001; Walsh et al., 2002) . The amyloid hypothesis states that accumulation of Aβ in the brain is the primary influence driving AD pathogenesis (Hardy and Selkoe, 2002) . Thus, the amyloid hypothesis provides the prime target for AD therapy and preventing Aβ production and aggregation as well as removing Aβ from the brain is considered to be preventive and therapeutic (Citron, 2010) .
Anti-Aβ immunotherapy is considered to be one of the most efficacious means of clearing Aβ deposits from the brain. Immunization of AD mouse models with synthetic Aβ prevented or reduced Aβ deposits and improved their memory and learning deficits (Schenk et al., 1999; Janus et al., 2000; Morgan et al., 2000) . These impressive results prompted initiation of phase I/II clinical trials to evaluate the safety and tolerability of aggregated Aβ vaccination. Clinical trials of peptide Aβ vaccine (AN-1792) brought to light the problems associated with the modality. Approximately, 6% of AD patients subjected to the Aβ vaccine developed aseptic T-lymphocyte meningoenchephalitis and/or Fc-mediated brain inflammation, which caused discontinuation of the trial (Check, 2002; Orgogozo et al., 2003) . Only 20% of AD patients developed anti-Aβ antibodies in the vaccine trial (Gilman et al., 2005) , indicating that most AD patients might not have an adequate immune response to Aβ vaccination due to aging and low immunogenicity of Aβ (Monsonego et al., 2001; Monsonego, 2005) . Cerebral hemorrhages were found in patients subjected to the Aβ vaccine trial (Ferrer et al., 2004; Uro-Coste et al., 2010) . Such hemorrhages appeared to be associated with increases in vascular amyloid deposits after immunization, which may be detrimental to endothelial cells and blood-brain barrier (BBB) (Pfeifer et al., 2002; Ferrer et al., 2004; Wilcock et al., 2004; Lee et al., 2005; Racke et al., 2005) . Therefore, the next generation of vaccines will need to overcome these problems associated with Aβ (AN-1792) vaccination.
To avoid the T-cell mediated side effects, we previously constructed an adenovirus vector encoding 11 tandem repeats of Aβ1-6 fused to the receptor-binding domain (Ia) of Pseudomonas exotoxin A, AdPEDI-(Aβ1-6) 11 (Kim et al., 2005) . Aβ1-6 lacks T cell epitopes of Aβ (Cribbs et al., 2003; Agadjanyan et al., 2005; Journal of Neuroimmunology 244 (2012) 70-83 
